Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort
| Autor: | Isabelle Bos, Gwendoline Peyratout, Yvonne Freund-Levi, Ellen Elisa De Roeck, Mara ten Kate, Kristel Sleegers, Susan Baker, Mikel Tainta, Lutz Frölich, Giovanni B. Frisoni, Cristina Legido-Quigley, Karen Meersmans, Andrey Kormilitzin, Abdul Hye, Valerija Dobricic, Alison L. Baird, Alberto Lleó, Régis Bordet, Johannes Streffer, Isabel Sala, Sneha N Anand, Lorena Rami, B. Paul Morgan, Silvy Gabel, Julius Popp, Noel J. Buckley, Olivier Blin, José Luis Molinuevo, Sarah Westwood, Angharad R. Morgan, Frans R.J. Verhey, Pieter Jelle Visser, Magda Tsolaki, Martinez-Lage P, Rik Vandenberghe, Alejo J. Nevado-Holgado, Simon Lovestone, Lars Bertram, Henrik Zetterberg, Anders Wallin, Philip Scheltens, Peter Johannsen, Nicholas J. Ashton, Charlotte E. Teunissen, Petronella Kettunen, Sebastiaan Engelborghs, Stephanie J.B. Vos, Frederik Barkhof, Liu Shi, Jill C. Richardson |
|---|---|
| Přispěvatelé: | University of Oxford, King‘s College London, University of Gothenburg (GU), Cardiff University, Maastricht University [Maastricht], Janssen Research & Development, VU University Medical Center [Amsterdam], University Hospitals Leuven [Leuven], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), University of Antwerp (UA), Vrije Universiteit Brussel (VUB), Vlaams Instituut voor Biotechnologie [Ghent, Belgique] (VIB), Université de Genève = University of Geneva (UNIGE), Istituto Centro San Giovanni di Dio Fatebenefratelli, Partenaires INRAE, Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Marseille (APHM), GlaxoSmithKline [Stevenage, UK] (GSK), GlaxoSmithKline [Headquarters, London, UK] (GSK), Université de Lille, CHU Lille, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Universitat Pompeu Fabra [Barcelona] (UPF), Sahlgrenska Academy at University of Gothenburg [Göteborg], AHEPA University General Hospital [Thessaloniki], Hospital de la Santa Creu i Sant Pau, Lausanne University Hospital, Center for Research and Advanced Therapies CITA-Alzheimer Foundation [San Sebastián], Copenhagen University Hospital, Karolinska University Hospital [Stockholm], Universität Heidelberg [Heidelberg] = Heidelberg University, Universität zu Lübeck = University of Lübeck [Lübeck], Steno Diabetes Center, University of Oslo (UiO), Institutes of Neurology and Healthcare Engineering, UCL, London, Sahlgrenska University Hospital [Gothenburg], UK Dementia Research Institute (UK DRI), University College of London [London] (UCL), UCL, Institute of Neurology [London], UCB Pharma S.A.[Braine-l'Alleud], UCB Pharma [Brussels], Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, MUMC+: MA Med Staf Spec Psychiatrie (9), Faculty of Arts and Philosophy, Clinical sciences, Neuroprotection & Neuromodulation, Neurology, Educational Science, Rissman, R, Radiology and nuclear medicine, Amsterdam Neuroscience - Neurodegeneration |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Apolipoprotein E Oncology Male MILD COGNITIVE IMPAIRMENT Alzheimer’s disease amyloid-β biomarkers plasma proteomics Apolipoprotein E4 PROGRESSION Disease Proteomics GUIDELINES Cohort Studies ddc:616.89 0302 clinical medicine MARKERS BLOOD-BASED BIOMARKER Biomarker discovery Medicine(all) biology General Neuroscience DEMENTIA General Medicine Blood Proteins Middle Aged CEREBROSPINAL-FLUID BIOMARKERS Alzheimer's disease Blood proteins Magnetic Resonance Imaging amyloid-beta 3. Good health Psychiatry and Mental health Clinical Psychology Body Burden Female Sample collection Life Sciences & Biomedicine Research Article EXPRESSION medicine.medical_specialty Amyloid beta tau Proteins 03 medical and health sciences Alzheimer Disease Internal medicine medicine Dementia Humans Amyloid-β Cognitive Dysfunction Biology Aged Science & Technology business.industry [SCCO.NEUR]Cognitive science/Neuroscience Neurosciences LECTIN medicine.disease Cerebral Amyloid Angiopathy PATHOLOGY 030104 developmental biology ROC Curve Positron-Emission Tomography biology.protein Neurosciences & Neurology Human medicine Geriatrics and Gerontology business 030217 neurology & neurosurgery |
| Zdroj: | Westwood, S, Baird, A L, Anand, S N, Nevado-Holgado, A J, Kormilitzin, A, Shi, L, Hye, A, Ashton, N J, Morgan, A R, Bos, I, Vos, S J B, Baker, S, Buckley, N J, Ten Kate, M, Scheltens, P, Teunissen, C E, Vandenberghe, R, Gabel, S, Meersmans, K, Engelborghs, S, De Roeck, E E, Sleegers, K, Frisoni, G B, Blin, O, Richardson, J C, Bordet, R, Molinuevo, J L, Rami, L, Wallin, A, Kettunen, P, Tsolaki, M, Verhey, F, Lléo, A, Sala, I, Popp, J, Peyratout, G, Martinez-Lage, P, Tainta, M, Johannsen, P, Freund-Levi, Y, Frölich, L, Dobricic, V, Legido-Quigley, C, Bertram, L, Barkhof, F, Zetterberg, H, Morgan, B P, Streffer, J, Visser, P J & Lovestone, S 2020, ' Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort ', Journal of Alzheimer's Disease, vol. 74, no. 1, pp. 213-225 . https://doi.org/10.3233/JAD-190434 Journal of Alzheimer's Disease Journal of Alzheimer's Disease, 2020, 74 (1), pp.213-225. ⟨10.3233/JAD-190434⟩ JOURNAL OF ALZHEIMERS DISEASE r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Journal of Alzheimer's Disease, 74(1), 213-225. IOS Press Journal of Alzheimer's disease, vol. 74, no. 1, pp. 213-225 Journal of Alzheimer's disease Journal of Alzheimer's Disease, Vol. 74, No 1 (2020) pp. 213-225 |
| ISSN: | 1387-2877 |
| Popis: | We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential trials participants for PET or cerebrospinal fluid measures of Alzheimer's disease (AD) pathology. This study sought to undertake validation of these candidate plasma biomarkers in a large, multi-center sample collection. Targeted plasma analyses of 34 proteins with prior evidence for prediction of in vivo pathology were conducted in up to 1,000 samples from cognitively healthy elderly individuals, people with mild cognitive impairment, and in patients with AD-type dementia, selected from the EMIF-AD catalogue. Proteins were measured using Luminex xMAP, ELISA, and Meso Scale Discovery assays. Seven proteins replicated in their ability to predict in vivo amyloid pathology. These proteins form a biomarker panel that, along with age, could significantly discriminate between individuals with high and low amyloid pathology with an area under the curve of 0.74. The performance of this biomarker panel remained consistent when tested in apolipoprotein E ɛ4 non-carrier individuals only. This blood-based panel is biologically relevant, measurable using practical immunocapture arrays, and could significantly reduce the cost incurred to clinical trials through screen failure. ispartof: JOURNAL OF ALZHEIMERS DISEASE vol:74 issue:1 pages:213-225 ispartof: location:Netherlands status: published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|